We are proud to announce the AL QASSIMI HOSPITAL, Sharjah, Dr Arif Al Nooryani, Chief Executive Officer & Head of Cardiac Centre for being appointed as Center of…

PulseCath BV is listed by Silicon Review under “30 Most Valuable Brands of the Year 2022″. We are really honoured and proud to be part of this. Thank…

Great achievement in Germany: NUB status 1 reimbursement for iVAC 2L in Germany again, with a record of #300 hospitals! Especially during these uncertain times, this is another significant support…

💡 Together with our partner EUKON S.r.l.e. we are exhibiting JIM-GISE Interventional Cardiology Congress on 9-11 February, 2023 at Rosa Grand Hotel in Milan including a dynamic Fellows Course on 8…

Another milestone reached. We are proud to announce the achievement of product registration for iVAC 2L in Malaysia. The first 2 successful iVAC 2L cases were performed at…

⚡️GHP Magazine Announces the Winners of the 2022 Technology Awards⚡️ Global Health & Pharma Magazine (GHP) awarded PulseCath with the Technology Awards for Best Heart Failure Pumping Functions…

PulseCath is proud sponsor at CSI FOCUS D-HF, December 9-10, 2022 in Frankfurt. Want to learn more about iVAC 2L, pulsatile percutaneous ventricular assist device, for protected high-risk…

It is with deep sadness that we inform you about the passing of Dr. Yoram Karmon, PhD- CEO & President.Dr. Yoram Karmon passed away unexpectedly by a septic…

The firm is expanding its global distribution, generating innovation and new products to broaden the Company’s product portfolio to become the world’s circulatory support leader. Farmington, MI –…

PulseCath has been recognized as one of the “Top 20 Companies Who Are Escalating Innovation in The Market in 2022”  by Global Business Leaders Magazine. We are really…